Citations

Showing 10 of 108083 citations.

Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder
Wingerchuk, Dean M. , McCormick, Dana, Barron, Sasha, Simone, Laura, Jarzylo, Larissa A., Weinshenker, Brian G.

Mayo Clinic

Journal of Managed Care & Specialty Pharmacy | November 25, 2022 | Volume: 28 | Issue: 12-a Suppl | Pages: S3-S27

10.18553/jmcp.2022.28.12-a.s1 | PMID 36427336 Get It

Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation
Day, Julia, Gehring, Karin , Zienius, Karolis , Grosshans, David R. , Taphoorn, Martin, Li, Jing , Brown, Paul D. , Kirkman, Matthew Anthony , Taphoorn, Martin

Mayo Clinic

Cochrane Database of Systematic Reviews | November 25, 2022 | Volume: 2022 | Issue: 11 | Pages: No page available

10.1002/14651858.cd011335.pub3 | PMID 36427235 Get It

Predicting 60–4 visual field tests using 3D facial reconstruction
Dogahe, Sepideh Jamali, Mousavi, Seyedmostafa Sadegh, Khanna, Cheryl L. , Jamali Dogahe, Sepideh, Garmany, Armin , Sadegh Mousavi, Seyedmostafa, Khanna, Cheryl L

Mayo Clinic

British Journal of Ophthalmology | November 25, 2022 | Volume: 108 | Issue: 1 | Pages: 112-116

10.1136/bjo-2022-321651 | PMID 36428007 Get It

Background Despite, the potential clinical utility of 60–4 visual fields, they are not frequently used in clinical practice partly, due to the purported impact of facial contour on field defects. The purpose of this study was to design and test an artificial intelligence-driven platform to predict facial structure-dependent visual field defects on 60–4 visual field tests. Methods Subjects with no ocular pathology were included. Participants were subject to optical coherence tomography, 60–4 Swedish interactive thresholding algorithm visual field tests and photography. The predicted visual field was compared with observed 60–4 visual field results in subjects. Average and point-specific sensitivity, specificity, precision, negative predictive value, accuracy, and F1-scores were primary outcome measures. Results 30 healthy were enrolled. Three-dimensional facial reconstruction using a convolution neural network (CNN) was able to predict facial contour-dependent 60–4 visual field defects in 30 subjects without ocular pathology. Overall model accuracy was 97%±3% and 96%±3% and the F1-score, dependent on precision and sensitivity, was 58%±19% and 55%±15% for the right eye and left eye, respectively. Spatial-dependent model performance was observed with increased sensitivity and precision within the far inferior nasal field reflected by an average F1-score of 76%±20% and 70%±29% for the right eye and left eye, respectively. Conclusions This pilot study reports the development of a CNN-enhanced platform capable of predicting 60–4 visual field defects in healthy controls based on facial contour. Further study with this platform may enhance understanding of the influence of facial contour on 60–4 visual field testing.
Beyond Neutrophils for Predicting Relapse and Remission in Ulcerative Colitis
El‐Zimaity, Hala , Riddell, Robert H. , Pai, Rish K. , Bernstein, Çharles N. , Shaffer, Seth R. , Bernstein, Charles Noah

Mayo Clinic

Journal of Crohn's and Colitis | November 25, 2022 | Volume: 17 | Issue: 5 | Pages: 767-776

10.1093/ecco-jcc/jjac178 | PMID 36426876 Get It

AbstractBackground and AimsThis study examines colonic histological features in ulcerative colitis [UC] in endoscopic remission to determine which cell types and biopsy sites best predict a patient’s likelihood of remaining in remission.MethodsThis is a retrospective chart, endoscopy and histology review of 166 patients with UC in endoscopic remission followed in a single inflammatory bowel disease practice over a median of 6 years [range, 2–11 years]. Clinical remission was based on global physician assessment and colonoscopy reports, and clinical relapse on chart review. Histological features of previous injury and also number and location of plasma cells and eosinophils were assessed. We evaluated all of these features semi-quantitatively using a standard set of illustrations for the grade to maintain consistency. Multiple logistic regression and survival analyses were used to identify features associated with relapse.ResultsClinical relapse occurred in 44 patients. Ulceration, especially in the left colon, was highly predictive of relapse. In the absence of acute inflammation of ulceration, the variables most predictive of relapse were increased plasma cells in the basal 20% of the lamina propria, and eosinophils in the left colon. The variable most predictive of persistent remission was the presence of intra-epithelial eosinophils whether in the surface epithelium or within crypts, especially in the right colon. Lamina propria eosinophils [grade > 2] throughout the colon predicted relapse.ConclusionIn the absence of neutrophils or ulceration, left-sided plasmacytosis in the basal 20% of the lamina propria and increased lamina propria eosinophils provide the best indicators of relapse in UC in clinical and endoscopic remission.
Stereotactic radiosurgery and local control of brain metastases from triple-negative breast cancer
Niranjan, Ajay , Hess, Judith, Antonios, Joseph , Zhang, Michael Y. , Ross, Richard B. , Pikis, Stylianos , Deibert, Christopher P., Lee, Cheng-chia, Langlois, Anne-Marie, Mathieu, David , Peker, Selçuk , Samancı, Yavuz , Rusthoven, Chad G. , Chiang, Veronica , Wei, Zhishuo , Lunsford, L. Dade , Sheehan, Jason P. , Mathieu, David , Kowalchuk, Roman O. , Braunstein, Steve , Yang, Huai‐Che , Trifiletti, Daniel M.

Mayo Clinic

Journal of Neurosurgery | November 25, 2022 | Volume: 138 | Issue: 6 | Pages: 1608-1614

10.3171/2022.10.jns221900 | PMID 36433878 Get It

OBJECTIVE Stereotactic radiosurgery (SRS) is an effective treatment for intracranial metastatic disease, but its role in triple-negative breast cancer requires further study. Herein, the authors report overall survival (OS) and local tumor control in a multiinstitutional cohort with triple-negative breast cancer metastases treated with SRS. METHODS Patients treated from 2010 to 2019 at 9 institutions were included in this retrospective study if they had biopsy-proven triple-negative breast cancer with intracranial metastatic lesions treated with SRS. Patients were excluded if they had undergone prior SRS, whole-brain radiation therapy, or resection of the metastatic lesions. A retrospective chart review was conducted to determine OS, local control, and treatment efficacy. RESULTS Sixty-eight patients with 315 treated lesions were assessed. Patients had a median Karnofsky Performance Status of 80 (IQR 70–90) and age of 57 years (IQR 48–67 years). Most treated patients had 5 or fewer intracranial lesions, with 34% of patients having a single lesion. Treated lesions were small, having a median volume owf 0.11 cm3 (IQR 0.03–0.60 cm3). Patients were treated with a median margin dose of 18 Gy (IQR 18–20 Gy) to the median 71% isodose line (IQR 50%–84%). Overall, patients had a 1-year OS of 43% and 2-year OS of 20%. Most patients (88%) were followed until death, by which time local tumor progression had occurred in only 7% of cases. Furthermore, 76% of the lesions demonstrated regression. Tumor volume was correlated with local tumor progression (p = 0.012). SRS was very well tolerated, and only 3 patients (5%) developed symptomatic radiation necrosis. CONCLUSIONS SRS is a safe and efficacious treatment for well-selected patients with triple-negative breast cancer, especially for those with a favorable performance status and small- to moderate-volume metastatic lesions.
TELOMERE LENGTH OF PERIPHERAL BLOOD MONONUCLEAR CELLS IS ASSOCIATED WITH DISCHARGE DISPOSITION IN OLDER TRAUMA PATIENTS
Goswami, Julie , Ramachandran, Dhanya , Mahony, C , Howick, Annelise S, Price-Troska, Tammy, Thompson, Riley J., Spears, Grant M. , Bailey, Kent R. , Patnaik, Mrinal S., Passos, João F. , Park, Myung S., MacArthur, Taleen A. , Mahony, Cillian R, Passos, João F , Patnaik, Mrinal S., Ferrer, Alejandro

Mayo Clinic

Shock | November 25, 2022 | Volume: 59 | Issue: 3 | Pages: 327-333

10.1097/shk.0000000000002059 | PMID 36427074 Get It

ABSTRACT Introduction: Little is known regarding peripheral blood mononuclear cell telomere length (PBMC-TL) and response to traumatic injury. The objective of this study was to characterize the role of PBMC-TL in coagulation and clinical outcomes after injury. Methods: Plasma and buffy coats were prospectively collected from trauma patients and healthy volunteers. DNA was purified and PBMC-TL quantified by quantitative polymerase chain reaction. Thrombin generation kinetics were expressed as lag time (in minutes), peak height (in nanometers), time to peak (in minutes), and endogenous thrombin potential (in nM × min). Results are in median and quartiles [Q1, Q3]. P < 0.05 was considered significant (Wilcoxon rank sum testing). Results: Forty-two younger patients (21 [20, 22] years, 69% were male) and 39 older patients (62 [61, 64] years, 79% were male) were included. There was no significant difference in Clinical Frailty Scores between groups. Younger patients had longer total PBMC-TL (0.40 Mb [0.30, 0.49] vs. 0.29 Mb [0.23, 0.33], P < 0.001) and longer average PBMC-TL per chromosome (4.3 kb [3.3, 5.3] vs. 3.2 kb [2.5, 3.7], P < 0.001). When older patients were stratified by 50th percentile of PBMC-TL, there were no differences in thrombin generation; however, those with shorter telomeres were less likely to be discharged home (29% vs. 77%, P = 0.004). Older patients in the bottom quartile of PBMC-TL had shorter lag time (2.78 min [2.33, 3.00] vs. 3.33 min [3.24, 3.89], P = 0.030) and were less likely to be discharged home (22% vs. 90%, P = 0.006) than those in the top quartile of PBMC-TL. Multivariable logistic regression models revealed both increased age and shorter PBMC-TL to be independent predictors of discharge disposition other than home. Conclusion: In older trauma patients, shorter PBMC-TL is associated with accelerated initiation of thrombin generation and lower likelihood of being discharged to home.
A practical guide to the development and deployment of deep learning models for the Orthopedic surgeon: part I
Nwachukwu, Benedict U. , Martin, R. Kyle , Kelly, Bryan T. , Pearle, Andrew D. , Pareek, Ayoosh , Oeding, Jacob F. , Williams, Riley J. , Karlsson, Jón , Camp, Christopher L. , Ranawat, Anil S.

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | November 25, 2022 | Volume: 31 | Issue: 2 | Pages: 382-389

10.1007/s00167-022-07239-1 | PMID 36427077 Get It

AbstractDeep learning has a profound impact on daily life. As Orthopedics makes use of this rapid escalation in technology, Orthopedic surgeons will need to take leadership roles on deep learning projects. Moreover, surgeons must possess an understanding of what is necessary to design and implement deep learning‐based project pipelines. This review provides a practical guide for the Orthopedic surgeon to understand the steps needed to design, develop, and deploy a deep learning pipeline for clinical applications. A detailed description of the processes involved in defining the problem, building the team, acquiring and curating the data, labeling the data, establishing the ground truth, pre‐processing and augmenting the data, and selecting the required hardware is provided. In addition, an overview of unique considerations involved in the training and evaluation of deep learning models is provided. This review strives to provide surgeons with the groundwork needed to identify gaps in the clinical landscape that deep learning models may be able to fill and equips them with the knowledge needed to lead an interdisciplinary team through the process of creating novel deep‐learning‐based solutions to fill those gaps.
Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Nedved, Adrienne, Maddocks, Kami J. , Nowakowski, Grzegorz S.

Mayo Clinic

The Oncologist | November 25, 2022 | Volume: 28 | Issue: 3 | Pages: 199-207

10.1093/oncolo/oyac256 | PMID 36648324 Get It

Abstract Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 24% of new cases of B-cell non-Hodgkin lymphoma in the US each year. Up to 50% of patients relapse or are refractory (R/R) to the standard first-line treatment option, R-CHOP. The anti-CD19 monoclonal antibody tafasitamab, in combination with lenalidomide (LEN), is an NCCN preferred regimen for transplant-ineligible patients with R/R DLBCL and received accelerated approval in the US (July 2020) and conditional marketing authorization in Europe (August 2021) and other countries, based on data from the L-MIND study. The recommended dose of tafasitamab is 12 mg/kg by intravenous infusion, administered in combination with LEN 25 mg for 12 cycles, followed by tafasitamab monotherapy until disease progression or unacceptable toxicity. Tafasitamab + LEN is associated with durable responses in patients with R/R DLBCL. The majority of clinically significant treatment-associated adverse events are attributable to LEN and can be managed with dose modification and supportive therapy. We provide guidelines for the management of patients with R/R DLBCL treated with tafasitamab and LEN in routine clinical practice, including elderly patients and those with renal and hepatic impairment, and advice regarding patient education as part of a comprehensive patient engagement plan. Our recommendations include LEN administration at a reduced dose if required in patients unable to tolerate the recommended dose. No dose modification is required for tafasitamab in special patient populations.
Intraoperative Blood Pressure Variability and Early Postoperative Stroke: A Case-Control Study
Morales, Diana J. Valencia , Garbajs, Nika Zorko , Tawfic, Sarah, Jose, Thulasee , Laporta, Mariana L. , Schroeder, Darrell R. , Valencia Morales, Diana J , Tawfic, Sarah S, Jose, Thulasee , Schroeder, Darrell , Weingarten, Toby N. , Šprung, Juraj

Mayo Clinic

The American Surgeon™ | November 25, 2022 | Volume: 89 | Issue: 12 | Pages: 5191-5200

10.1177/00031348221136578 | PMID 36426383 Get It

Background This study aims to assess the association of postoperative stroke with intraoperative hemodynamic variability and transfusion management. Methods In this case-control study, adult patients (≥ 18 years) who had a stroke within 72 hours of a surgical procedure were matched to 2 control patients according to age, sex, and procedure type. Primary risk factors assessed were intraoperative fluid administration, blood product transfusion, vasopressor use, and measures of variability in systolic and diastolic blood pressure and heart rate: maximum, minimum, range, SD, and average real variability. The variables were analyzed with conditional logistic regression, which accounted for the 1:2 matched case-control study design. Results Among 687 581 procedures, we identified 64 postoperative strokes (incidence, 9.3 [95% CI, 7.2-11.9] strokes per 100 000 procedures). These cases were matched with 128 controls. Stroke cases had higher Charlson cmorbidity index scores than did controls (P = .046). Blood pressure and heart rate variability measures were not associated with stroke. The risk of stroke was increased with red blood cell (RBC) transfusion (odds ratio [OR], 14.82; 95% CI, 3.40-64.66; P < .001), vasopressor use (OR, 3.91; 95% CI, 1.59-9.60; P = .003), and longer procedure duration (OR, 1.23/h; 95% CI, 1.01-1.51; P = .04). Multivariable analysis of procedure duration, RBC transfusion, and vasopressor use showed that only RBC transfusion was independently associated with an increased risk of stroke (OR, 10.10; 95% CI, 2.14-47.72; P = .004). Conclusions Blood pressure variability was not associated with an increased risk of postoperative stroke; however, RBC transfusion was an independent risk factor.
A comprehensive review of cerebral oximetry in cardiac surgery
Moore, Christina , Yu, Soojie , Aljure, Oscar , Moore, Christina C , Aljure, Oscar D

Mayo Clinic

Journal of Cardiac Surgery | November 24, 2022 | Volume: 37 | Issue: 12 | Pages: 5418-5433

10.1111/jocs.17232 | PMID 36423259 Get It